ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Mangoceuticals Inc

Mangoceuticals Inc (MGRX)

2.30
-0.01
( -0.43% )
Updated: 11:18:59

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
2.30
Bid
2.29
Ask
2.32
Volume
15,102
2.2961 Day's Range 2.37
2.10 52 Week Range 16.80
Market Cap
Previous Close
2.31
Open
2.35
Last Trade
1
@
2.3008
Last Trade Time
11:37:14
Financial Volume
$ 35,159
VWAP
2.3281
Average Volume (3m)
3,855,787
Shares Outstanding
2,400,000
Dividend Yield
-
PE Ratio
-0.60
Earnings Per Share (EPS)
-3.84
Revenue
731k
Net Profit
-9.21M

About Mangoceuticals Inc

Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was i... Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc. Show more

Sector
Health & Allied Services,nec
Industry
Health & Allied Services,nec
Website
Headquarters
Dallas, Texas, USA
Founded
-
Mangoceuticals Inc is listed in the Health & Allied Services sector of the NASDAQ with ticker MGRX. The last closing price for Mangoceuticals was $2.31. Over the last year, Mangoceuticals shares have traded in a share price range of $ 2.10 to $ 16.80.

Mangoceuticals currently has 2,400,000 shares outstanding. The market capitalization of Mangoceuticals is $5.54 million. Mangoceuticals has a price to earnings ratio (PE ratio) of -0.60.

MGRX Latest News

Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

Dallas, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (β€œMangoRx” or the β€œCompany”), a company focused on developing, marketing, and selling men’s health and...

MangoRx Announces Formation of Strategy and Alternatives Committee

Dallas, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (β€œMangoRx” or the β€œCompany”),Β a company focused on developing, marketing, and selling men’s health and...

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (β€œMangoRx” or the β€œCompany”), a company focused on developing, marketing, and selling men’s health and...

MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLITΒ AS PART OF NASDAQ COMPLIANCE PLAN

DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (β€œMangoRx” or the β€œCompany”), a company focused on developing, marketing, and selling a variety of men’s health...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.09-3.765690376572.392.542.27850152.42376142CS
4-0.15-6.122448979592.452.652.11699762.42488448CS
12-1.9075-45.33571004164.20757.6592.138557874.27971206CS
26-1.42-38.17204301083.7216.82.146549196.05779763CS
52-5.65-71.06918238997.9516.82.126970445.85485411CS
156-60.7-96.34920634926364.0412.121424169.94117919CS
260-60.7-96.34920634926364.0412.121424169.94117919CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HCWBHCW Biologics Inc
$ 1.63
(453.29%)
353.67M
APLMApollomics Inc
$ 0.1575
(64.23%)
560.02M
JWELJowell Global Ltd
$ 3.0367
(55.73%)
6.37M
ACRSAclaris Therapeutics Inc
$ 2.94
(43.41%)
10.7M
SINTSiNtx Technologies Inc
$ 2.92
(43.14%)
45.28M
CMAXCareMax Inc
$ 0.724
(-56.90%)
558.2k
QMMMQMMM Holdings Limited
$ 3.51
(-52.11%)
921.12k
NGNENeurogene Inc
$ 20.39
(-40.92%)
844.05k
AILEiLearningEngines Inc
$ 0.9701
(-35.33%)
3.7M
SGDSafe and Green Development Corporation
$ 1.85
(-30.45%)
246.71k
APLMApollomics Inc
$ 0.1575
(64.23%)
565.22M
HCWBHCW Biologics Inc
$ 1.63
(453.29%)
355.43M
ELABElevai Labs Inc
$ 0.0231
(4.52%)
159.72M
NVDANVIDIA Corporation
$ 141.0092
(-0.68%)
101.3M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 21.1117
(12.84%)
68.77M

MGRX Discussion

View Posts
KeepItRealistic KeepItRealistic 1 month ago
$MGRX if company captures only 1/10th of one percent of that market, it gives you $49.3m in Revenues 😮

Let that SINK IN …

https://finance.yahoo.com/news/mangorx-addresses-49-3-billion-113000298.html
πŸ‘οΈ0
KeepItRealistic KeepItRealistic 1 month ago
$MGRX excellent exposure to capital

Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform,, is pleased to announce it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit, which will be taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 22nd to Wednesday, October 23rd, 2024, in Nassau, Bahamas.

Jacob Cohen, Founder and CEO, is scheduled to present on Wednesday, October 23rd at 11:10 EDT. Jacob will also be fielding investor questions during the summit.

The Centurion One Capital 2nd Annual Bahamas Summit will feature public and private companies across various industries that will be given the opportunity to present to some of the most prominent venture capital, family office, private equity firms, high net worth individuals and institutional investors in the growth space attending from Canada, the United States, and abroad. For registration details, please click here.

Summit Details:

Event: Centurion One Capital 2nd Annual Bahamas Summit
Format: Presentations, Q&A, Panel Discussions and 1 X 1 Investor Meetings
Dates: Tuesday, October 22nd and Wednesday, October 23rd, 2024
Time: 9:00 AM EDT – 4:00 PM EDT
Venue: Rosewood Baha Mar Hotel

About Centurion One Capital

Centurion One Capital (β€œCenturion One”) is the premier independent Investment Banking firm dedicated to fueling the growth and success of growth companies in North America. With an unwavering commitment to delivering comprehensive financial solutions and strategic guidance, Centurion One is a trusted strategic partner and catalyst to propel issuers to unlock their full potential. Our team comprises seasoned professionals who combine extensive financial expertise with deep knowledge of various sectors. We take a proactive and results-driven approach, working closely with our clients to develop tailored strategies and execute transactions that maximize value and drive long-term success.

Centurion One - Empowering Growth. Driving Innovation. Partnering for Success.
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
MGRX: However, the ONLY way this firm could make their stock SOAR in price, would be if they launch a NEW pill that is guaranteed to make ANY man's 'hot dog' 12-inches long, & 3-inches thick!!!!
πŸ‘οΈ0
glenn1919 glenn1919 1 month ago
MGRX.......................................https://stockcharts.com/h-sc/ui?s=MGRX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
MGRX: NICE!!!!!!
πŸ‘οΈ0
tw0122 tw0122 1 month ago
$3.65 + 37% Reverse split and β€œTRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.

Mangoceuticals, Inc. (NASDAQ: MGRX) (β€œMangoRx” or the β€œCompany”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, β€œTRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling appetite. Clinical trials have shown that Tirzepatide can deliver weight reductions of up to 20% in obese individuals. The phase 3 SURMOUNT-1 clinical trial showed that a significant percentage of participants achieved weight loss of over 15-20% in just 72 weeks, marking it as a viable option and alternative for effective, long-term weight management?.

Further, in the SURMOUNT-4 trial, Tirzepatide not only helped patients achieve substantial weight loss, but it also helped patients maintain their progress over an extended period. After 88 weeks of treatment, patients experienced a total weight reduction of up to 25%, with nearly 90% maintaining at least 80% of their initial weight loss?.

MangoRx’s TRIM formulation now provides Tirzepatide treatment in an easy-to-use oral dissolvable tablet, eliminating the need for injections and enhancing patient convenience.

The launch of TRIM is a key strategic move for MangoRx, as the Company looks to strengthen its foothold in the expanding weight management sector. As demand for non-invasive, clinically proven solutions rises, we believe MangoRx is positioned to capitalize on this market growth.

Jacob Cohen, CEO and Founder of MangoRx, stated, β€œWe are excited to bring TRIM to market, offering consumers a cutting-edge, oral alternative to conventional weight loss injections. TRIM’s introduction marks another significant step for MangoRx as we continue to innovate and meet the changing needs of patients. By launching TRIM, we are delivering a solution that enhances patient convenience without sacrificing efficacy. As demand for GLP-1-based treatments continues to climb, our telemedicine platform ensures that patients have access to safe, reliable options.”

According to a study performed by Roots Analysis, the global GLP-1 market is projected to grow from $49.3 billion in 2024 to $157.5 billion by 2035, with the obesity segment expected to capture the majority share by 2035, due to rising obesity rates and demand for effective treatments.

With the addition of TRIM, MangoRx now offers patients both Tirzepatide and Semaglutide options for weight loss treatments. Following the successful release of our Semaglutide-based oral dissolvable tablet branded as SLIM, patients can choose from two advanced, highly effective GLP-1 receptor agonists, each tailored to meet different needs in their weight management journey. Both products are currently listed on the MangoRx website and available with a doctor’s prescription, providing expanded access to cutting-edge weight loss solutions through its telemedicine platform.

πŸ‘οΈ0
KeepItRealistic KeepItRealistic 1 month ago
$MGRX 👀

https://x.com/keeprealistic/status/1847095691505791237?s=46&t=IJ2EAuutIm5R5c1kklP3-w

πŸ‘οΈ0
KeepItRealistic KeepItRealistic 2 months ago
$MGRX mega news below (huge market)

Market Correction incoming…

β€œDallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (β€œMangoRx” or the β€œCompany”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, β€œTRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling appetite. Clinical trials have shown that Tirzepatide can deliver weight reductions of up to 20% in obese individuals. The phase 3 SURMOUNT-1 clinical trial showed that a significant percentage of participants achieved weight loss of over 15-20% in just 72 weeks, marking it as a viable option and alternative for effective, long-term weight management?.

Further, in the SURMOUNT-4 trial, Tirzepatide not only helped patients achieve substantial weight loss, but it also helped patients maintain their progress over an extended period. After 88 weeks of treatment, patients experienced a total weight reduction of up to 25%, with nearly 90% maintaining at least 80% of their initial weight loss?.

MangoRx’s TRIM formulation now provides Tirzepatide treatment in an easy-to-use oral dissolvable tablet, eliminating the need for injections and enhancing patient convenience.

The launch of TRIM is a key strategic move for MangoRx, as the Company looks to strengthen its foothold in the expanding weight management sector. As demand for non-invasive, clinically proven solutions rises, we believe MangoRx is positioned to capitalize on this market growth.

Jacob Cohen, CEO and Founder of MangoRx, stated, β€œWe are excited to bring TRIM to market, offering consumers a cutting-edge, oral alternative to conventional weight loss injections. TRIM’s introduction marks another significant step for MangoRx as we continue to innovate and meet the changing needs of patients. By launching TRIM, we are delivering a solution that enhances patient convenience without sacrificing efficacy. As demand for GLP-1-based treatments continues to climb, our telemedicine platform ensures that patients have access to safe, reliable options.”

According to a study performed by Roots Analysis, the global GLP-1 market is projected to grow from $49.3 billion in 2024 to $157.5 billion by 2035, with the obesity segment expected to capture the majority share by 2035, due to rising obesity rates and demand for effective treatments.

With the addition of TRIM, MangoRx now offers patients both Tirzepatide and Semaglutide options for weight loss treatments. Following the successful release of our Semaglutide-based oral dissolvable tablet branded as SLIM, patients can choose from two advanced, highly effective GLP-1 receptor agonists, each tailored to meet different needs in their weight management journey. Both products are currently listed on the MangoRx website and available with a doctor’s prescription, providing expanded access to cutting-edge weight loss solutions through its telemedicine platform.”





πŸ‘οΈ0
KeepItRealistic KeepItRealistic 2 months ago
β€œOn October 1, 2024, the Company delivered an Advance Notice to the Purchaser and sold the Purchaser 2,000,000 shares of common stock pursuant to the terms of the ELOC for $0.26 per share for a total of $521,016, net of fees, discounts and expenses”
πŸ‘οΈ0
KeepItRealistic KeepItRealistic 2 months ago
$MGRX company has been selling shares which explains the retrace

https://www.otcmarkets.com/filing/html?id=17875545&guid=9OL-kaoudyTyDVh
👍 1
Penny chatter Penny chatter 2 months ago
Looks like this guy is just a promoter
πŸ‘οΈ0
power11 power11 2 months ago
AS THEY SAY IN ITALIAN : PUMPO AND DUMPO !!!!
PURE DOG SHIT WRAPPED IN CAT SHIT
👍 1
TrendTrade2016 TrendTrade2016 2 months ago
dilute dilute...drop like a rock into open
πŸ‘οΈ0
glenn1919 glenn1919 2 months ago
MGRX..............................https://stockcharts.com/h-sc/ui?s=MGRX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 3 months ago
Thin L2 !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 3 months ago
It’s moving, waiting on more volume !
πŸ‘οΈ0
mining101 mining101 3 months ago
Big week upcoming
πŸ‘οΈ0
glenn1919 glenn1919 4 months ago
MGRX..........................https://stockcharts.com/h-sc/ui?s=MGRX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Penny2Dime Penny2Dime 4 months ago
Nice!
πŸ‘οΈ0
KeepItRealistic KeepItRealistic 4 months ago
$MGRX huge

https://x.com/nxtplse/status/1816808590138568792?s=46&t=IJ2EAuutIm5R5c1kklP3-w

πŸ‘οΈ0
mining101 mining101 4 months ago
New highs are in sight
πŸ‘οΈ0
KeepItRealistic KeepItRealistic 4 months ago
$MGRX more solid news

https://ca.finance.yahoo.com/news/mangorx-initiates-efficacy-studies-patented-121500395.html
πŸ‘οΈ0
KeepItRealistic KeepItRealistic 4 months ago
$MGRX game changer

https://stocktwits.com/RandySays/message/580033852

πŸ‘οΈ0
KeepItRealistic KeepItRealistic 4 months ago
$MGRX like what I heard…

πŸ‘οΈ0
KeepItRealistic KeepItRealistic 4 months ago
$MGRX keep your 👀 on it for follow up on …

https://finance.yahoo.com/news/mangorx-introduce-oral-semaglutide-tirzepatide-123000451.html

β€œMangoRx plans to have the products available for customers on the company’s telemedicine platform in the beginning of the 3rd quarter with β€˜Slim’ and β€˜Trim’ competitively priced at $299/month and $399/month, respectively. MangoRx is committed to advancing the treatment of obesity and related conditions and is dedicated to improving the lives of patients worldwide.”

3rd Qtr started July 1st

This was the news that pushed it past $1
πŸ‘οΈ0
mining101 mining101 4 months ago
Break .50 soon
πŸ‘οΈ0
glenn1919 glenn1919 4 months ago
MGRX........................https://stockcharts.com/h-sc/ui?s=MGRX&p=W&b=5&g=0&id=p86431144783






πŸ‘οΈ0
Invest-in-America Invest-in-America 4 months ago
MGRX: For their next "news", maybe MGRX can get a pre-fight promo going to the effect that both Jake Paul & Mike Tyson use their stuff!!
πŸ‘οΈ0
mining101 mining101 4 months ago
Rebound to 1
πŸ‘οΈ0
Zardiw Zardiw 4 months ago
I'm wondering if you're pissed off at me for some reason.....can't PM........but whatever it is, I'm sorry if I did/said anything that you didn't like.....

Hans@DDAmanda.com
760 702-2009

Z
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 months ago
MGRX: Might be the kind of news this Firm has long needed. (I.e., no more silly promos, ads, etc. ---- now, serious business.)
πŸ‘οΈ0
PinkPennies PinkPennies 4 months ago
MGRX nice news https://finance.yahoo.com/news/mangorx-announces-strategic-partnership-expansion-121500806.html
πŸ‘οΈ0
valleybenedetto valleybenedetto 5 months ago
Mango written up by JP Morgan Fund!

https://athletechnews.com/jp-morgan-targets-weight-loss-drugs-with-500m-fund/?s=09
👍️ 1 💯 1
Golden Cross Golden Cross 5 months ago
$MGRX MangoRx to Introduce β€œMOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances https://www.stocktitan.net/news/MGRX/mango-rx-to-introduce-mojo-pharmaceutical-compounded-formula-xetrg1zk54sn.html
πŸ‘οΈ0
Carjockey2 Carjockey2 6 months ago
Haaaaa..

I am the new crypto coin gal..

Lol
πŸ‘οΈ0
valleybenedetto valleybenedetto 6 months ago
Trade em up. No more marriages
πŸ‘οΈ0
Carjockey2 Carjockey2 6 months ago
Nice news but I'm done with this one.

πŸ‘οΈ0
valleybenedetto valleybenedetto 6 months ago
Nice news today. Partnered with CrakMedia..same firm that brought BlueChew to 200m revs
πŸ‘οΈ0
Carjockey2 Carjockey2 6 months ago
Again...

Don't include me on your posts like you did all day today..

Does that work for you..works for me..

Cyber stalking is illegal...

Back to your 4 jobs you go..

πŸ‘οΈ0
crowin crowin 6 months ago
Again my point that everything is about you!

Get back with the family, they miss you!


Please keep your post about MGRX.
πŸ‘οΈ0
Carjockey2 Carjockey2 6 months ago
LMAO

You have had time to stalk me for 10 years..YES 10 years..


I am happily retired..

No 4 jobs for me..

Follow the right traders you won't have to work 4 jobs..

After following me for 10 years you should be happily retired with your family what have you been doing wrong







πŸ‘οΈ0
crowin crowin 6 months ago
I Have a life and do not hang out around here allday, just mornings.

What is wrong with that ?

Take care of the family like i do.

4 business and family is my priority...
Whats yours?
πŸ‘οΈ0
crowin crowin 6 months ago
Everything you post is about you. Stop it!

You missed out today for a quick buck.

Whats next?

Stop stalking me when I make money without you!
Go and enjoy the Grand baby!

Granny, will you please focus on me and not IHUB!

I miss you granny......
πŸ‘οΈ0
Carjockey2 Carjockey2 6 months ago
If you I really owned shares here you wouldn't be posting five times to me on a board you'd be celebrating, so I guess we know what's up..

We all know you stalk me but that's even crazy..
πŸ‘οΈ0
Carjockey2 Carjockey2 6 months ago
Lolzzzz

Awesome day here..

$MGRX


What's weee??

This was your last post in February..lol

Reverse Stock split to risky here

Silly bird.. is it difficult pretending you own shares of something you hated when it runs???
πŸ‘οΈ0
Carjockey2 Carjockey2 6 months ago
Great day everybody congratulations..

$MGRX got a bona..

😉
πŸ‘οΈ0
Invest-in-America Invest-in-America 6 months ago
MGRX: Are my MGRX shares 'rising-from-the-ashes' now, following a rather disappointing Close today??? (At 32% UP in the Post-M right now, might be so.)
πŸ‘οΈ0
Invest-in-America Invest-in-America 6 months ago
MGRX: Hey "Invest-in-America", CLOWN!! Why don't you flush your pet PUSSYCAT down that toilet, FOOL!!! (Which is likely the ONLY 'pussy' you ever got, STUPID!!) WHY??? Because our MGRX COMEBACK is gonna make Tom Brady's look like those stupid 'BUCKS' of Florida never even scored ONE POINT in that game!!!
πŸ‘οΈ0
Invest-in-America Invest-in-America 6 months ago
MGRX: See today's final 'CHART', below!!

πŸ‘οΈ0
Invest-in-America Invest-in-America 6 months ago
MGRX: Come on, you dead-cat, BOUNCE!!! For the sake of us BIG-FAT-&-GREASY Amerikanos!!! And heck, you have one pill to make mens' DICKS big & fat --- and now another pill to make their OBESITY-BODIES "slim & trim"!!! Why not do BOTH in just one, tasty, fat pill???!!!

////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
And see BELOW, what my own 'Personal Financial Planner' said to me early today, when I asked him what he thought about me tossin' some bucks at MGRX stock ---
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock